Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health marketplace connecting patients with in-network therapists and psychiatrists, Los Angeles CA, raised $65M+. Insurance-covered access in all 50 states.
Rula is a Los Angeles, California-based mental health marketplace founded in 2019 that connects patients with in-network licensed therapists and psychiatrists through an online directory and matching platform. The company has raised over $65 million and has built insurance coverage across all 50 US states, making it one of the broadest-access in-network therapy platforms in the country. Rula handles provider credentialing, insurance contracting, billing, and claims processing on behalf of its network clinicians.\n\nRula's marketplace allows patients to search for therapists and psychiatrists by specialty, insurance, location, language, and availability, with real-time availability shown and direct booking enabled. The platform is designed to reduce the common friction points in finding in-network mental health care: lengthy wait times, confusing insurance directory inaccuracies, and billing surprises. Rula verifies insurance eligibility before the first appointment and provides upfront cost estimates so patients know their expected out-of-pocket responsibility.\n\nThe company has focused heavily on therapist experience and provider satisfaction, offering competitive reimbursement rates, automated billing, flexible scheduling, and dedicated support to attract and retain high-quality clinicians. Rula competes with Headway, Alma, and Grow Therapy in the therapist marketplace and infrastructure segment. With its 50-state insurance footprint and consumer-friendly search experience, Rula is positioned as an accessible alternative to the fragmented and often outdated directories maintained by health plans.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.